Australian scientists have named the Nigella sativa (nigella sativa) plant, which grows in North Africa and West Asia, as a potential component of an anti-coronavirus drug, but clinical trials will be required to introduce it into pharmaceuticals. This was announced on August 4 by an immunologist, doctor of medical sciences Vladislav Zhemchugov.
“In any case, clinical studies are needed to see the result. But a lot of means of blocking the cytokine storm are already known, they are all very effective. And in general, another question is whether it is necessary to block it. That is, it is not always necessary to do this. Each patient has a specific situation “, – commented on the TV channel REN TV research of Pearls.
According to the expert, clinical trials are expensive and time-consuming procedures, so there is a small chance that this flower will be released into the “big farm”.
The day before, MedicalXpress published an article by Professor Kanees Fatima Shad of the Australian Catholic University (ACU), which said that the thymoquinone contained in nigella sativa can bind to the S-protein of the SARS-CoV-2 coronavirus and prevent the virus from causing lung infection.
On July 29, it was reported that scientists at the University of Göttingen in Germany have developed nanobodies that effectively block the SARS-CoV-2 coronavirus and its dangerous new variants. It was noted that alpacas helped scientists create nanobodies. Researchers immunized the animals, then took blood samples and isolated about a billion different antibodies.
According to the latest data from the portal Worldometer, the number of cases of coronavirus infection in the world exceeded 200 million, more than 4.2 million people died from the consequences of the disease, over 180 thousand patients recovered.
All relevant information on the situation with the coronavirus is available on the websites stopcoronavirus.rf and access to all.rf, as well as by the hashtag #WeVeTogether. Coronavirus hotline: 8 (800) 2000-112.